Recent News

• 09.09.2025 - IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer’s Detection
• 09.02.2025 - IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada
• 08.28.2025 - IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette’s Syndrome
• 08.27.2025 - IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.”
• 08.25.2025 - IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
• 08.19.2025 - IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer’s Trial
• 08.05.2025 - IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression
• 07.23.2025 - IGC Pharma to Present Advanced AI Platforms for Alzheimer’s Disease at the AAIC 2025
• 07.21.2025 - IGC Pharma’s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Recent Filings

• 08.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.18.2025 - DEF 14A Other definitive proxy statements
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2025 - PRE 14A Other preliminary proxy statements
• 07.28.2025 - EFFECT Notice of Effectiveness
• 07.24.2025 - CORRESP Correspondence
• 07.23.2025 - UPLOAD SEC-generated letter
• 07.18.2025 - S-3 Registration statement under Securities Act of 1933
• 06.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 06.17.2025 - 8-K Current report